Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

The pathogenesis and management of hypertension in diabetic kidney disease.

Van Buren PN, Toto RD.

Med Clin North Am. 2013 Jan;97(1):31-51. doi: 10.1016/j.mcna.2012.10.003. Epub 2012 Nov 27. Review.

PMID:
23290728
3.

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S, Warren SR, Peduzzi P; VA NEPHRON-D Investigators..

Clin J Am Soc Nephrol. 2009 Feb;4(2):361-8. doi: 10.2215/CJN.03350708. Epub 2008 Dec 31.

4.

[Risk and prevention of diabetic nephropathy].

Ravera M, Re M, Deferrari G.

G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9. Italian.

PMID:
17922442
5.

Recommendations for the management of special populations: renal disease in diabetes.

Raij L.

Am J Hypertens. 2003 Nov;16(11 Pt 2):46S-49S. Review.

PMID:
14625161
6.

Calcium channel blockers in the prevention of end stage renal disease: a review.

Derwa A, Peeters P, Vanholder R.

Acta Clin Belg. 2004 Jan-Feb;59(1):44-56. Review.

PMID:
15065696
7.
8.
9.

Angiotensin receptor blockers: RAAS blockade and renoprotection.

Ruilope LM.

Curr Med Res Opin. 2008 May;24(5):1285-93. doi: 10.1185/030079908X291921 . Epub 2008 Mar 25. Review.

PMID:
18366863
10.

Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.

Krairittichai U, Chaisuvannarat V.

J Med Assoc Thai. 2009 May;92(5):611-7.

PMID:
19459520
11.

Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.

Suzuki H, Kanno Y, Nakamoto H, Okada H, Sugahara S.

Clin Exp Hypertens. 2005 Feb-Apr;27(2-3):129-38.

PMID:
15835375
12.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L.

Semin Nephrol. 2004 Mar;24(2):147-57. Review.

PMID:
15017527
13.
14.

Arterial hypertension and proteinuria in pediatric chronic kidney disease.

Simonetti GD, Bucher BS, Tschumi S, Lava SA, Bianchetti MG.

Minerva Pediatr. 2012 Apr;64(2):171-82. Review.

PMID:
22495191
15.

An update on proteinuric chronic kidney disease: the dual-goal approach.

Hirsch S.

Cleve Clin J Med. 2008 Oct;75(10):705-13. Review.

PMID:
18939386
16.

Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis.

Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF.

Lancet. 2015 May 23;385(9982):2047-56. doi: 10.1016/S0140-6736(14)62459-4. Review.

17.

ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?

Pappoe LS, Winkelmayer WC.

Drugs Aging. 2010 Feb 1;27(2):87-94. doi: 10.2165/11316430-000000000-00000.

PMID:
20104936
18.

Renal protection and antihypertensive drugs: current status.

Salvetti A, Mattei P, Sudano I.

Drugs. 1999 May;57(5):665-93. Review.

PMID:
10353294
19.

Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?

Sternlicht H, Bakris GL.

Blood Purif. 2016;41(1-3):139-43. doi: 10.1159/000441264. Epub 2016 Jan 15. Review.

20.

The current state of RAAS blockade in the treatment of hypertension and proteinuria.

Kalaitzidis RG, Bakris GL.

Curr Cardiol Rep. 2009 Nov;11(6):436-42. Review.

PMID:
19863868

Supplemental Content

Support Center